Cargando…

Atomoxetine Increased Effect over Time in Adults with Attention‐Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double‐Blind, Placebo‐Controlled, Randomized Trials

INTRODUCTION: Changes in the magnitude of efficacy throughout 26 weeks of atomoxetine treatment, along with impact of dosing, were evaluated in adults with ADHD from two randomized, double‐blind, placebo‐controlled studies. AIMS: Pooled placebo (n = 485) and atomoxetine (n = 518) patients, dosed 25,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wietecha, Linda A., Clemow, David B., Buchanan, Andrew S., Young, Joel L., Sarkis, Elias H., Findling, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069588/
https://www.ncbi.nlm.nih.gov/pubmed/26922462
http://dx.doi.org/10.1111/cns.12533
_version_ 1782460965855428608
author Wietecha, Linda A.
Clemow, David B.
Buchanan, Andrew S.
Young, Joel L.
Sarkis, Elias H.
Findling, Robert L.
author_facet Wietecha, Linda A.
Clemow, David B.
Buchanan, Andrew S.
Young, Joel L.
Sarkis, Elias H.
Findling, Robert L.
author_sort Wietecha, Linda A.
collection PubMed
description INTRODUCTION: Changes in the magnitude of efficacy throughout 26 weeks of atomoxetine treatment, along with impact of dosing, were evaluated in adults with ADHD from two randomized, double‐blind, placebo‐controlled studies. AIMS: Pooled placebo (n = 485) and atomoxetine (n = 518) patients, dosed 25, 40, 60, 80 (target dose), or 100 mg daily, were assessed. Change from baseline in Conners’ Adult ADHD Rating Scale–Investigator Rated Scale: Screening Version (CAARS) total ADHD symptoms score and Adult ADHD Investigator Symptom Rating Scale (AISRS) total score were analyzed using mixed‐model repeated measures, with least squares mean change, effect size, and response rate calculated at 1, 2, 4, 8, 12, 16, 22, and 26 weeks. RESULTS: Decreases on CAARS for atomoxetine‐ versus placebo‐treated patients were consistently statistically significantly greater at every time point beginning at one week (P ≤ 0.006, 0.28 effect size). By 4 weeks, comparison was −13.19 compared with −8.84 (P < 0.0001, 0.45 effect size). By 26 weeks, mean change was −15.42 versus −9.71 (0.52 effect size); increase in effect size over time was most pronounced in the 80 mg group (0.82 effect size). AISRS demonstrated similar results. Atomoxetine response rate (CAARS 50% decrease) continued to increase throughout 26 weeks. CONCLUSIONS: Atomoxetine treatment in adults with ADHD was associated with small effect sizes after 4 weeks and moderate effect sizes by 6 months of treatment. The data support increased effect size and response rate over time during longer‐term treatment at target dose.
format Online
Article
Text
id pubmed-5069588
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50695882016-11-01 Atomoxetine Increased Effect over Time in Adults with Attention‐Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double‐Blind, Placebo‐Controlled, Randomized Trials Wietecha, Linda A. Clemow, David B. Buchanan, Andrew S. Young, Joel L. Sarkis, Elias H. Findling, Robert L. CNS Neurosci Ther Original Articles INTRODUCTION: Changes in the magnitude of efficacy throughout 26 weeks of atomoxetine treatment, along with impact of dosing, were evaluated in adults with ADHD from two randomized, double‐blind, placebo‐controlled studies. AIMS: Pooled placebo (n = 485) and atomoxetine (n = 518) patients, dosed 25, 40, 60, 80 (target dose), or 100 mg daily, were assessed. Change from baseline in Conners’ Adult ADHD Rating Scale–Investigator Rated Scale: Screening Version (CAARS) total ADHD symptoms score and Adult ADHD Investigator Symptom Rating Scale (AISRS) total score were analyzed using mixed‐model repeated measures, with least squares mean change, effect size, and response rate calculated at 1, 2, 4, 8, 12, 16, 22, and 26 weeks. RESULTS: Decreases on CAARS for atomoxetine‐ versus placebo‐treated patients were consistently statistically significantly greater at every time point beginning at one week (P ≤ 0.006, 0.28 effect size). By 4 weeks, comparison was −13.19 compared with −8.84 (P < 0.0001, 0.45 effect size). By 26 weeks, mean change was −15.42 versus −9.71 (0.52 effect size); increase in effect size over time was most pronounced in the 80 mg group (0.82 effect size). AISRS demonstrated similar results. Atomoxetine response rate (CAARS 50% decrease) continued to increase throughout 26 weeks. CONCLUSIONS: Atomoxetine treatment in adults with ADHD was associated with small effect sizes after 4 weeks and moderate effect sizes by 6 months of treatment. The data support increased effect size and response rate over time during longer‐term treatment at target dose. John Wiley and Sons Inc. 2016-02-28 /pmc/articles/PMC5069588/ /pubmed/26922462 http://dx.doi.org/10.1111/cns.12533 Text en © 2016 Eli Lilly and Company. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Wietecha, Linda A.
Clemow, David B.
Buchanan, Andrew S.
Young, Joel L.
Sarkis, Elias H.
Findling, Robert L.
Atomoxetine Increased Effect over Time in Adults with Attention‐Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double‐Blind, Placebo‐Controlled, Randomized Trials
title Atomoxetine Increased Effect over Time in Adults with Attention‐Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double‐Blind, Placebo‐Controlled, Randomized Trials
title_full Atomoxetine Increased Effect over Time in Adults with Attention‐Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double‐Blind, Placebo‐Controlled, Randomized Trials
title_fullStr Atomoxetine Increased Effect over Time in Adults with Attention‐Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double‐Blind, Placebo‐Controlled, Randomized Trials
title_full_unstemmed Atomoxetine Increased Effect over Time in Adults with Attention‐Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double‐Blind, Placebo‐Controlled, Randomized Trials
title_short Atomoxetine Increased Effect over Time in Adults with Attention‐Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double‐Blind, Placebo‐Controlled, Randomized Trials
title_sort atomoxetine increased effect over time in adults with attention‐deficit/hyperactivity disorder treated for up to 6 months: pooled analysis of two double‐blind, placebo‐controlled, randomized trials
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069588/
https://www.ncbi.nlm.nih.gov/pubmed/26922462
http://dx.doi.org/10.1111/cns.12533
work_keys_str_mv AT wietechalindaa atomoxetineincreasedeffectovertimeinadultswithattentiondeficithyperactivitydisordertreatedforupto6monthspooledanalysisoftwodoubleblindplacebocontrolledrandomizedtrials
AT clemowdavidb atomoxetineincreasedeffectovertimeinadultswithattentiondeficithyperactivitydisordertreatedforupto6monthspooledanalysisoftwodoubleblindplacebocontrolledrandomizedtrials
AT buchananandrews atomoxetineincreasedeffectovertimeinadultswithattentiondeficithyperactivitydisordertreatedforupto6monthspooledanalysisoftwodoubleblindplacebocontrolledrandomizedtrials
AT youngjoell atomoxetineincreasedeffectovertimeinadultswithattentiondeficithyperactivitydisordertreatedforupto6monthspooledanalysisoftwodoubleblindplacebocontrolledrandomizedtrials
AT sarkiseliash atomoxetineincreasedeffectovertimeinadultswithattentiondeficithyperactivitydisordertreatedforupto6monthspooledanalysisoftwodoubleblindplacebocontrolledrandomizedtrials
AT findlingrobertl atomoxetineincreasedeffectovertimeinadultswithattentiondeficithyperactivitydisordertreatedforupto6monthspooledanalysisoftwodoubleblindplacebocontrolledrandomizedtrials